Entry Type
Name
Value
Parent Entry
Pharmacology Data Field
Near 100%
Medroxyprogesterone Acetate (API)
Pharmacology Data Field
88% bound to serum albumin, no binding to SHBG or CBG
Medroxyprogesterone Acetate (API)
Pharmacology Data Field
90-96.2%
Dienogest (API)
Pharmacology Data Field
90% bound to serum albumin, 10% free. No binding to SHBG or CBG.
Dienogest (API)
Pharmacology Data Field
CYP3A4. No hepatic first pass effects after oral intake.
Medroxyprogesterone Acetate (API)
Pharmacology Data Field
- Oral: 70-75%
- Subdermal implant: 100%
Etonogestrel (API)
Pharmacology Data Field
95.5-99% bound. 66% to albumin, 32% to SHBG.
Etonogestrel (API)
Pharmacology Data Field
76-85%
Drospirenone (API)
Pharmacology Data Field
95-96% bound to serum albumin. No binding to SHBG or CBG.
Drospirenone (API)
Pharmacology Data Field
99%
Gestodene (API)
Pharmacology Data Field
47.5% bound to SHBG, 50% to serum albumin, 2.5% unbound
Levonorgestrel (API)
Pharmacology Data Field
76% as etonogestrel.
Desogestrel (API)
Pharmacology Data Field
As etonogestrel: 58% to serum albumin, 38% to SHBG, 3.5% unbound. (Grandi)
32% to SHBG, 66% to albumin, 2% free. (Schindler)
Desogestrel (API)
Pharmacology Data Field
As a prodrug of norethindrone that forms no other metabolites, the pharmacology of lynestrenol is essentially the same as norethindrone.
Lynestrenol (API)
Pharmacology Data Field
< 2 h from multiple oral administration of 75 μg desogestrel (Grandi)
1.15 h (Schindler)
Desogestrel (API)
Pharmacology Data Field
- Oral: 1.5 h; 2-3 h
- Subdermal implant: 4 days
Etonogestrel (API)
Pharmacology Data Field
2 h
Dienogest (API)
Pharmacology Data Field
1-2 h
Drospirenone (API)
Metabolites Data Field
Antagonist
3β-Hydroxychlormadinone Acetate (Metabolite)
Metabolites Data Field
Antagonist
15β-Hydroxycyproterone Acetate (Metabolite)